Getting Closer to Targeted Therapies for NASH: Are You Ready?
Premiere Date: Sunday, November 14, 2021This activity offers CE credit for:
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Monday, November 14, 2022
Note: Credit Is No Longer Available
 | Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD, (Moderator) President, Inova Medicine Services Chairman, Clinical Research, Inova Health System Professor and Chairman of Department of Medicine Inova Fairfax Medical Campus Falls Church, VA |
 | Rohit Loomba, MD, MHSc Director, NAFLD Research Center Professor of Medicine Director of Hepatology and Vice Chief Division of Gastroenterology Adjunct Professor, Division of Epidemiology University of California at San Diego San Diego, CA |
 | Mazen Noureddin, MD, MHSc Director, Fatty Liver Program Karsh Division of Gastroenterology and Hepatology Comprehensive Transplant Center Cedars-Sinai Medical Center Los Angeles, CA |
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease that ranges from isolated hepatic steatosis (e.g., nonalcoholic fatty liver [NAFL]) to inflammatory steatosis with or without fibrosis (e.g., nonalcoholic steatohepatitis [NASH]). While the disease course of NAFL is generally benign, patients with NASH are at significant risk for progression to fibrosis and cardiometabolic diseases.
Although early diagnosis is critical to achieve optimal outcomes, NASH is a “silent” disease without obvious signs or symptoms. Diagnostic tests are limited, with poor sensitivity and/or specificity. Thus, early diagnosis requires a high index of clinical suspicion and appropriate follow-up. While there are currently no approved agents for the treatment of NASH, several clinical pathways have been established to optimize current care. Novel agents are urgently in development, and clinicians need to stay abreast of these important emerging therapies.
This CME Outfitters digital satellite symposium will address these challenges in diagnosing and treating NASH. Expert faculty will advise on appropriate testing, current clinical algorithms, and results from relevant late-stage clinical trials.
At the end of this CE activity, participants should be able to:
- Select appropriate noninvasive diagnostic tests to stratify risk in patients with NAFLD/NASH.
- Incorporate currently recommended therapies and interventions for preventing serious or fatal complications of disease/comorbidities into the plan of care for patients with NAFLD/NASH.
- Identify the molecular basis of pharmacologic agents in late-stage clinical trials for the treatment of NASH.
Supported by an educational grant from Novo Nordisk.
Hepatologists, gastroenterologists, endocrinologists, primary care physicians (PCPs), PAs, nurse practitioners (NPs), nurses, and pharmacists
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Younossi reports that he receives research support from Bristol Myers Squibb Company; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Merck & Co, Inc.; and Siemens. He is a consultant for Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novo Nordisk; Siemens; and Terns Pharmaceuticals, Inc.
Dr. Loomba reports his institution receives grants from Allergan; Astrazeneca; Boehringer-Ingelheim; Bristol Myers Squibb Company; Eli Lilly and Company; Galectin Therapeutics; Galmed Pharmaceuticals; Genfit; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Inventiva; Janssen Pharmaceuticals, Inc.; Madrigal Pharmaceuticals, Inc.; Merck & Co., Inc.; NGM Biopharmaceuticals; Pfizer Inc.; and Sonic Incytes. He receives research support from DOD PRCRP (W81XWH-18-2-0026); NCATS (5UL1TR001442); NHLBI (P01HL147835); NIAAA (U01AA029019); NIEHS (5P42ES010337); and NIDDK (U01DK06173, R01DK106419, R01DK121378, R01DK124318, P30DK120515). He is a consultant for 89bio, Inc.; Aardvark Therapeutics, Inc.; Altimmune; Alnylam Pharmaceuticals, Inc./ Regeneron Pharmaceuticals Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; AstraZeneca; Bristol Myer Squibb Company; CohBar, Inc.; Eli Lilly and Company; Galmed Pharmaceuticals; Gilead Sciences, Inc.; Glympse bio; HighTide Therapeutics Inc.; Inipharm; Intercept Pharmaceuticals, Inc.; Inventiva; Ionis Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Madrigal Pharmaceuticals, Inc.; Metacrine, Inc.; NGM Biopharmaceuticals; Novartis; Novo Nordisk; Merck & Co., Inc.; Pfizer Inc.; Sagimet Biosciences; Theratechnologies Inc.; and Viking Therapeutics. He is co-founder of Liponexus, Inc.
Dr. Noureddin reports he receives research support from Allergan; Bristol Myers Squibb Company; Conatus Pharmaceuticals Inc.; Enanta Pharmaceuticals, Inc.; Galectin Therapeutics Inc.; Galmed Pharmaceuticals; GENFIT; Gilead Sciences, Inc.; Madrigal Pharmaceuticals; Novartis; Pfizer Inc.; Shire; Viking Therapeutics; and Zydus Pharmaceuticals, Inc. He is serves on the advisory board for 89bio, Inc.; Blade Therapeutics; Echosens; Fractyl Health, Inc.; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novo Nordisk; Pfizer Inc.; Roche Diagnostics; Siemens; and Terns Pharmaceuticals, Inc. He is a stock shareholder (directly purchased) of Ananetos; Rivus Pharmaceuticals; and Viking Therapeutics, Inc.
Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.
Warren Beckman (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MM-121-111421-68
